Program
Varenicline
Also written as “varenicline”, “Varenicline Tartrate” and “varenicline (CP-526,555)”.
Its studies are mostly in Smoking Cessation · Dry Eye Syndromes · Smoking · Trigeminal Neuralgia · Cigarette Smoking, led by 6 companies.
Drug pageVarenicline: every studyMany companies study it; this page follows only the 44 they lead. All 254 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 320 open or running | phase 4since Jan 3, 2008 | Aug 29, 2005 | none ahead |
| Viatrisits history only | 60 open or running | phase 3since Jul 25, 2019 | Aug 15, 2018 | none ahead |
| Corxel Pharmaceuticalsits history only | 20 open or running | phase 3since May 13, 2022 | May 13, 2022 | none ahead |
| Rose Research Center | 20 open or running | phase 4since Jun 6, 2019 | Jun 6, 2019 | none ahead |
| Kriya Therapeuticsits history only | 11 open or running | phase 2since Apr 17, 2026 | Apr 17, 2026 | Feb 2029phase 2 · NCT07596485 |
| SRI Internationalits history only | 10 open or running | no phasesince Mar 8, 2006 | Mar 8, 2006 | none ahead |
Also a collaborator on its studies: GlaxoSmithKline.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Rose Research Center only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 6, 2019First study: phase 4 study in Smoking CessationFirst studyNCT04188106 · 26 enrolled · United States
- Dec 4, 2019Phase 3 study in Smoking CessationNCT04210180 · 25 enrolled · United States
TargetBeta
“Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cytisinerule | Achieve Life Sciences | phase 3 | 13 |
Studies
All 2 Rose Research Center leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04210180Smoking Cessation · United States | 3 | Completed | Oct 14, 2020 | 25 |
| NCT04188106Smoking Cessation · United States | 4 | Completed | Dec 15, 2019 | 26 |
How it is read
Names in the registry
- “varenicline”, 11 entries
- “Varenicline Tartrate”, 7 entries
- “Varenicline”, 6 entries
- “varenicline (CP-526,555)”, 6 entries
- “CP-526,555 (varenicline)”, 4 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 28 studies
- Dry Eye Syndromes, 6 studies
- Smoking, 2 studies
- Trigeminal Neuralgia, 1 study
- Cigarette Smoking, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.